Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran

Join Pharma | Login

	Editorial


	WALK THE EXTRA MILE
	Wednesday, April 2, 2025
	Global recognition to the Indian Pharmacopoeia (IP) as a book of standard has been a major issue the Indian pharmaceutical exporters, including the merchant exporters, have been facing for a long time now.
	Past Editorial...

TODAY'S NEWS


18:00 [IST]	Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran
17:00 [IST]	Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee
16:00 [IST]	Johnson & Johnson Global Survey reveals confidence in AI and medical technology to address personalized needs of aging population and alleviate burnout among HCPs
15:00 [IST]	Vera Therapeutics completes full enrollment in pivotal ORIGIN phase 3 trial for Atacicept in patients with IgA nephropathy
14:00 [IST]	Clinical Trials Information System designated as WHO primary registry
13:00 [IST]	EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer

more news >>

TOP NEWS


08:00 [IST]	Reciprocal tariff may pose significant challenge to growth of medical devices sector: AiMeD
08:00 [IST]	WB DCA files police complaint against threatening calls to DIs to stop inspections at sale premises & supply chains
08:00 [IST]	Ayush ministry needs to come up with new schemes and strategies to achieve targets: Parliamentary Panel
08:00 [IST]	Indian pharma poised to enhance affordability & accessibility of CAR-T cell therapy to combat cancer
08:00 [IST]	Indian healthcare sees urgent need for skill development to offset shortfall of doctors, nurses and paramedics
08:00 [IST]	CDSCO asks state regulators to keep vigil against use of two antibiotics in food-producing animals

more news >>

YESTERDAY'S NEWS


19:15 [IST]	Supreme Court issues notice to Roche on risiplam matter
18:00 [IST]	Biologit boosts patient safety with automated local literature monitoring solution for non-indexed sources
17:20 [IST]	The Good Bug presents clinically proven natural GLP-1 weight loss solution amid rising obesity rates in India
16:50 [IST]	Sova Health launches advanced microbiome tests & evidence-based precision supplements
16:40 [IST]	Aon reports rising healthcare costs with India among the fastest-growing medical markets
16:20 [IST]	Kapadia Hospital joins India’s first AI surgery revolution with MISSO, hailed by PM Modi

more news >>

INTERVIEW


All DIs in TN are fully competent to inspect manufacturing units as per Revised Schedule M: MN Sridhar
MN Sridhar, director of the Tamil Nadu Drugs Control Department

Past Interviews...

	What's New?

US tariff exemption to bolster Indian pharma global presence with supply of high quality medicines Insulin Aspart 100 Iu/ml, Pack Of 3 Ml Brivaracetam 100mg Tab Mebeverine 135mg Tab Levofloxacin 500mg 100ml Infusion

Opinion Poll

Will the introduction of Revised Schedule M by Union Health Ministry solve the issue of quality of Indian drugs?

YesNoCan't Say

View Past Poll

Corporate

Special Features

Features

Chronicle Pharmabiz Specials

Forthcoming Events

TENDERS & PROJECTS

	Tenders & Enquiries
	Pharma Projects

CORPORATE

	Company Profile
	Corporate Results
	Corporate X-ray
	Pharmabiz Studies of Top Companies

US FDA UPDATE

EXPORT & IMPORT

	Drug Export Procedures
	Drug Units With WHO GMP Certification
	Pharma Export Data
	Import Reg. Update

PHARMA LAWS & DOCUMENTS

LIST OF LABS & GOVT. BODIES

	Govt Recognised In-House R&D Units
	AICTE Boards & Committees
	List of Indian CROs
	List of CROs (International)
	Govt & approved labs of India
	List of State Drugs Controllers